Article PDF
Avoid common mistakes on your manuscript.
References
Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin 2005;55:10–30.
Silverberg E, Boring CC, Squires TS. Cancer Statistics 1990. CA Cancer J Clin 1990;40:9–26.
Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarci-noma. Am J Surg Pathol 1982;61:93–108.
Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95:593–6.
Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: Results of a prospective study. BMJ 1989; 298:147–51.
Li X, O’Malley BW. Unfolding the action of progesterone receptors. J Biol Chem 2003;278:39261–4.
Horwitz KB, Alexander PS. In situ photolinked nuclear proges-terone receptors of human breast cancer cells: Subunit molecular weights after transformation and translocation. Endocrinology 1983;113:2195–201.
Kastner P, Kurst A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two func-tionally different human progesterone receptor forms A and B. EMBOJ 1990;9:1603–14.
Giagrande P, Kimbrel E, Edwards D, McDonnell D. The opposing 6 transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000;20:3102–15.
Hovland AR, Powell RL, Takimoto GS, Jung L, Horowitz KB. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J Biol Chem 1998;272:5455–60.
Giangrande PH, Pollio G, McDonnell DP. Mapping and characterization of the functional domains responsible for the differ-ential activity of the A and B isoforms of the human progesterone receptor. Biol Chem 1997;32:889–900.
Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 1994;14:8356–64.
Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW, McDonnell DP. Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244–55.
Mulac-Jericevic B, Mullinax KA, DeMayo FJ, Lydon JP, Connelly OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isofbrm. Science 2000;289:1751–4.
De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene asso-ciated with endometrial cancer risk. PNAS 2002;99:12263–8.
Migliaccio A, Piccolo D, Castoria G, et al. Activation of the Src/p21/ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17:2008–18.
Fujimoto J, Ichigo S, Hirose R, Sagaguchi H, Tamaya T. Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J Steroid Biochem Mol Biol 1997;62:449–54.
Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. Cancer Res 1998; 58:1860–5.
Arnett-Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61:4576–82.
Smid-Koopman E, Kühne LCM, Hanekamp EE, et al. Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA and/or PR-B-expressing endometrial cancer cell lines. J Soc Gynecol Invest 2005;12:285–92.
Hanekamp EE, Gielen SCJP, DeRuiter PE, et al. Differences in invasive capacity of endometrial cancer cell lines expressing dif-ferent progesterone receptor isotypes: Possible involvement of cadherins. J Soc Gynecol Invest 2005;12:278–84.
Leblanc M, Poncelet C, Soriano D, et al. Alteration of CD44 and cadherin expression: Possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchow’s Arch 2001;438:78–85.
Hanekamp EE, Kühne EC, Smid-Koopman E, et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 2002;38(Suppl 6):S71–2.
Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003; 9:4190–9.
Leslie KK, Stein M-P, Kumar NS, et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 2005;96:32–41.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schwartz, P.E. Progesterone Isoforms and Endometrial Cancer. Reprod. Sci. 12, 219–221 (2005). https://doi.org/10.1016/j.jsgi.2005.02.013
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jsgi.2005.02.013